Renal Impairment: Clinical Trials

177 completed. 177 Phase 1, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	177	Completed 177
Phase 2	3	Completed 3

Follow Renal Impairment: new trials by email Literature Review of Renal Impairment trials Research Report on Renal Impairment

Trials (filtered) newest first · largest first

All 177 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function VC005 Tablets - Renal Impairment	Phase 1	Completed	Jiangsu vcare pharmaceutical technology co., LTD	32	2026-05-09	2026-08-20
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) MK-2828 - Chronic Kidney Failure, End-Stage Renal Disease	Phase 1	Completed	Merck Sharp & Dohme LLC	18	2026-03-02	2026-09-15
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls S-892216-PO - Renal Impairment	Phase 1	Completed	Shionogi	24	2025-10-16	2026-10-22
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment LY3537031 - Renal Impairment, Healthy	Phase 1	Completed	Eli Lilly and Company	31	2025-09-18	2026-04-24
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls BPN14770 - Renal Impairment	Phase 1	Completed	Shionogi	14	2025-08-25	2026-02-27
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) Opemalirsen (AZD2373) - Renal Impairment	Phase 1	Completed	AstraZeneca	35	2025-08-18	2026-06-26
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function ESK-001 - Renal Impairment	Phase 1	Completed	Alumis Inc	16	2025-04-23	2025-12-10
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function Petrelintide - Renal Impairment	Phase 1	Completed	Zealand Pharma	39	2025-04-15	2026-01-28
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination - Healthy Volunteer Study, Hepatic Impairment	Phase 1	Completed	Atea Pharmaceuticals, Inc.	28	2025-04-09	2026-07-31
A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010) Calderasib - Healthy, Renal Impairment	Phase 1	Completed	Merck Sharp & Dohme LLC	34	2025-04-07	2026-02-13
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234 AZD6234 - Renal Impairment	Phase 1	Completed	AstraZeneca	24	2025-02-24	2025-11-03
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 AZD5004 - Renal Impairment	Phase 1	Completed	AstraZeneca	16	2024-12-17	2025-06-08
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis BMS-986278 - Kidney Failure, Chronic, Healthy Volunteers	Phase 1	Completed	Bristol-Myers Squibb	27	2024-12-07	2025-10-14
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) Enlicitide - Healthy, Renal Impairment	Phase 1	Completed	Merck Sharp & Dohme LLC	27	2024-11-22	2026-10-20
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment AZD5462 - Renal Impairment	Phase 1	Completed	AstraZeneca	16	2024-11-18	2025-12-03
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants AZD4144 - Renal Impairment, End-stage Kidney Disease	Phase 1	Completed	AstraZeneca	41	2024-11-18	2026-04-07
Effect of Renal Impairment on Enpatoran Pharmacokinetics Enpatoran - Renal Impairment	Phase 1	Completed	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	34	2024-09-24	2026-05-01
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 AZD0780 - Renal Impairment	Phase 1	Completed	AstraZeneca	30	2024-08-02	2025-02-20
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects ANT3310, Meropenem - Renal Impairment	Phase 1	Completed	Antabio	41	2024-07-19	2025-07-29
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) MK-8527 - Renal Impairment	Phase 1	Completed	Merck Sharp & Dohme LLC	18	2024-06-20	2026-02-17

Showing 20 of 177. Sign in to see all of them.

Narrower conditions

Renal Insufficiency (177)  ·  Kidney Failure, Chronic (10)  ·  Kidney Diseases (9)  ·  Lymphoma, Follicular (5)  ·  Diabetes Mellitus, Type 2 (4)  ·  Renal Insufficiency, Chronic (4)  ·  Cardiomyopathies (2)  ·  Diabetes Mellitus (2)  ·  Anemia (1)  ·  Arthritis, Rheumatoid (1)  ·  COVID-19 (1)  ·  Heart Failure (1)  ·  Hepatitis C, Chronic (1)  ·  Hypertension (1)  ·  Mood Disorders (1)

Broader conditions

Female Urogenital Diseases (177)  ·  Female Urogenital Diseases and Pregnancy Complications (177)  ·  Male Urogenital Diseases (177)  ·  Urogenital Diseases (177)  ·  Urologic Diseases (177)  ·  Kidney Diseases (168)  ·  Chronic Disease (13)  ·  Disease Attributes (13)  ·  Pathologic Processes (13)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Renal Insufficiency, Chronic (8)  ·  Hemic and Lymphatic Diseases (7)  ·  Immune System Diseases (7)  ·  Cardiovascular Diseases (6)  ·  Immunoproliferative Disorders (6)

Interventions

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (2)  ·  AT-511 (2)  ·  Cefepime (2)  ·  Tablets (2)  ·  Tadalafil (2)  ·  2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1)  ·  3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1)  ·  4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one (1)  ·  ALKS 5461 (1)  ·  ALN-PCS (1)  ·  AZD4831 (1)  ·  AZD9977 (1)  ·  BI 456906 (1)  ·  BPN14770 (1)  ·  Cholestyramine Resin (1)

Sponsors

AstraZeneca (14)  ·  Merck Sharp & Dohme LLC (11)  ·  Novartis Pharmaceuticals (10)  ·  Pfizer (10)  ·  Bristol-Myers Squibb (4)  ·  Shionogi (4)  ·  AbbVie (3)  ·  Amgen (3)  ·  Astellas Pharma Global Development, Inc. (3)  ·  Bayer (3)  ·  Eisai Inc. (3)  ·  Janssen Research & Development, LLC (3)  ·  Sanofi (3)  ·  Takeda (3)  ·  Astellas Pharma Inc (2)

Countries

United States (107)  ·  Germany (28)  ·  China (10)  ·  Bulgaria (7)  ·  Hungary (6)  ·  Japan (5)  ·  New Zealand (5)  ·  Romania (5)  ·  Canada (4)  ·  Czechia (4)  ·  South Korea (4)  ·  Belgium (2)  ·  France (2)  ·  Moldova (2)  ·  Poland (2)

Top investigators

Thomas Marbury, MD (3)  ·  Horng H Chen, MD (2)

Results publications

PMID 21960668, PMID 23737404, PMID 24030917, PMID 24408516, PMID 24760402, PMID 24946021, PMID 25136024, PMID 25529979, PMID 26519231, PMID 28349386, PMID 28365033, PMID 28679468, PMID 28703316, PMID 29263061, PMID 29891610, PMID 30012756, PMID 30194585, PMID 30397067, PMID 30680407, PMID 31332068, PMID 31630870, PMID 31632000, PMID 32579796, PMID 32868037, PMID 33388951, PMID 33813736, PMID 34115385, PMID 34213819, PMID 34637151, PMID 35001638, PMID 35018553, PMID 35420493, PMID 35712797, PMID 36811175, PMID 37070852, PMID 37295665, PMID 37801266, PMID 37840155, PMID 38184489, PMID 38746989, PMID 38770818, PMID 39574348, PMID 39601078, PMID 42032338, PMID 42059789

NIH funding

2017 (4), 2018 (4), 2019 (2), 2008 (1), 2014 (1), 2023 (1)